Abstract
Colorectal cancer is a common malignancy, with the liver being the most frequent site of metastases. [(18)F] Fluorodeoxyglucose ([(18)F]FDG) positron emission tomography/computed tomography (PET/CT) has emerged as a valuable tool in detecting and evaluating liver metastases and extrahepatic disease. Herein, we present a case of a 76-year-old male with colorectal cancer associated with lung and liver metastases. The patient received 12 chemoimmunotherapy cycles and was then put on maintenance cetuximab; serial [(18)F]FDG PET/CT scans were utilized to evaluate treatment response. The patient exhibited a positive response to chemoimmunotherapy, with regression of rectal disease and resolution of pulmonary metastatic nodules. Serial [(18)F]FDG PET/CT scans unveiled three distinct necrotic patterns. The case report advocates that [(18)F]FDG PET/CT plays an important role in evaluating colorectal liver metastases (CRLM) response to treatment, identifying transient necrosis, early recurrence, and emphasizing the limitations of post-treatment CT scans in identifying early CRLM recurrence. Integrating functional imaging, particularly [(18)F]FDG PET/CT, promises for management monitoring and surveillance of CRLM patients.